PUBLISHER: TechSci Research | PRODUCT CODE: 1714254
PUBLISHER: TechSci Research | PRODUCT CODE: 1714254
Herceptin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Distribution Channel, By Region and Competition, 2020-2030F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The global Herceptin market was valued at USD 3.51 billion in 2024 and is projected to reach USD 4.92 billion by 2030, growing at a CAGR of 5.77% over the forecast period. This market is witnessing steady growth driven by the rising incidence of HER2-positive breast and gastric cancers. Herceptin (trastuzumab), a monoclonal antibody, has established itself as a foundational therapy in HER2-targeted treatment strategies. Increasing adoption of precision medicine, improvements in HER2 diagnostic testing, and integration of trastuzumab into clinical protocols for both early and metastatic stages of cancer are supporting market expansion. Enhanced survival outcomes and robust clinical backing continue to strengthen demand. Growth is further reinforced by advancements in diagnostic tools, rising healthcare investments, and the uptake of subcutaneous formulations that improve treatment convenience. The expanding biosimilar landscape is also broadening access, supporting global market growth while intensifying competition and driving innovation in delivery formats and combination therapies.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.51 Billion |
| Market Size 2030 | USD 4.92 Billion |
| CAGR 2025-2030 | 5.77% |
| Fastest Growing Segment | Stomach/Gastric Cancer |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of HER2-Positive Cancers
The escalating incidence of HER2-positive breast and gastric cancers is significantly boosting demand for Herceptin. HER2 overexpression, identified in a notable subset of patients, enables targeted therapy using trastuzumab. As breast cancer remains the most diagnosed cancer globally, the population eligible for HER2-directed treatments continues to rise. In the U.S., HER2-positive subtypes account for nearly 13.6% of female breast cancer cases, and the burden is similarly high in certain gastric and gastroesophageal cancers, particularly in East Asia and Eastern Europe. The rising need for precise and effective therapies has reinforced Herceptin's clinical value, making it a critical part of standard treatment regimens in oncology.
Key Market Challenges
Patent Expiry and Growing Biosimilar Competition
The expiration of Herceptin's patent protection has opened the market to numerous biosimilars, reshaping competitive dynamics. Regions like the U.S. and Europe have seen an influx of biosimilar alternatives, driving down prices and reducing the market share of the originator product. Healthcare systems, under pressure to optimize costs, are increasingly favoring biosimilars in treatment guidelines and procurement policies. This has intensified pricing pressure and limited brand differentiation. Manufacturers of Herceptin are responding through lifecycle management initiatives, including patient access programs and a strategic pivot toward newer combination therapies. However, sustaining profitability and market share amid widespread biosimilar adoption remains a significant challenge.
Key Market Trends
Shift Toward Combination and Sequential Therapies
The Herceptin market is evolving with a growing emphasis on combination and sequential treatment approaches. Clinicians are increasingly combining trastuzumab with chemotherapies, other biologics, and antibody-drug conjugates to improve outcomes in HER2-positive cancers. The incorporation of pertuzumab and docetaxel alongside trastuzumab, as well as the growing use of antibody-drug conjugates like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan, reflect this shift. These regimens have demonstrated superior efficacy in both metastatic and adjuvant settings. Sequential therapy-transitioning from trastuzumab to ADCs or TKIs-is also being adopted in cases of disease progression, extending Herceptin's role across multiple lines of treatment.
Key Market Players
- Roche Holding AG
- Pfizer Inc.
- Samsung Bioepis Co., Ltd.
- Amgen Inc.
- Celltrion Healthcare Co., Ltd.
- Biocon Limited
- Mylan N.V. (Viatris)
- Prestige Biopharma
- Shanghai Henlius Biotech, Inc.
- Dr. Reddy's Laboratories
Report Scope:
In this report, the Global Herceptin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Herceptin Market, By Product:
- Biologic
- Biosimilar
Herceptin Market, By Application:
- Breast Cancer
- Stomach/Gastric Cancer
- Others
Herceptin Market, By Distribution Channel:
- Hospital Pharmacy
- Specialty Pharmacy
- Others
Herceptin Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Herceptin Market.
Available Customizations:
Global Herceptin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Herceptin Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Biologic, Biosimilar)
- 5.2.2. By Application (Breast Cancer, Stomach/Gastric Cancer, Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Others)
- 5.2.4. By Company (2024)
- 5.2.5. By Region
- 5.3. Market Map
6. North America Herceptin Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Herceptin Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Application
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Mexico Herceptin Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Application
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Canada Herceptin Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Application
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Herceptin Market Outlook
7. Europe Herceptin Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Herceptin Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Application
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. Germany Herceptin Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Application
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Herceptin Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Application
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Herceptin Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Application
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Herceptin Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Application
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. France Herceptin Market Outlook
8. Asia-Pacific Herceptin Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Herceptin Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Application
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Herceptin Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Application
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. South Korea Herceptin Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Application
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. Japan Herceptin Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Application
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Herceptin Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Application
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Herceptin Market Outlook
9. South America Herceptin Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Herceptin Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Application
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Argentina Herceptin Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Colombia Herceptin Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Brazil Herceptin Market Outlook
10. Middle East and Africa Herceptin Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Herceptin Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Saudi Arabia Herceptin Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. UAE Herceptin Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.1. South Africa Herceptin Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porters Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Roche Holding AG
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Pfizer Inc.
- 14.3. Samsung Bioepis Co., Ltd.
- 14.4. Amgen Inc.
- 14.5. Celltrion Healthcare Co., Ltd.
- 14.6. Biocon Limited
- 14.7. Mylan N.V. (Viatris)
- 14.8. Prestige Biopharma
- 14.9. Shanghai Henlius Biotech, Inc.
- 14.10. Dr. Reddy's Laboratories
15. Strategic Recommendations
16. About Us & Disclaimer
